MDGL
Price
$221.98
Change
+$8.86 (+4.16%)
Updated
Dec 4, 6:59 PM EST
80 days until earnings call
RXRX
Price
$7.41
Change
+$0.02 (+0.27%)
Updated
Dec 4, 6:59 PM EST
107 days until earnings call
Ad is loading...

Compare predictions MDGL vs RXRX

Header iconMDGL vs RXRX Comparison
Open Charts MDGL vs RXRXBanner chart's image
Madrigal Pharmaceuticals
Price$221.98
Change+$8.86 (+4.16%)
Volume$136.86K
CapitalizationN/A
Recursion Pharmaceuticals
Price$7.41
Change+$0.02 (+0.27%)
Volume$2.32M
CapitalizationN/A
View a ticker or compare two or three
MDGL vs RXRX Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
MDGL vs. RXRX commentary
Dec 05, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Buy and RXRX is a Buy.

COMPARISON
Comparison
Dec 05, 2023
Stock price -- (MDGL: $221.98 vs. RXRX: $7.41)
Brand notoriety: MDGL and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 33% vs. RXRX: 62%
Market capitalization -- MDGL: $3.9B vs. RXRX: $1.41B
MDGL [@Biotechnology] is valued at $3.9B. RXRX’s [@Biotechnology] market capitalization is $1.41B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 0 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 0 green, 5 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, RXRX is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 6 TA indicator(s) are bullish while RXRX’s TA Score has 7 bullish TA indicator(s).

  • MDGL’s TA Score: 6 bullish, 4 bearish.
  • RXRX’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а +12.51% price change this week, while RXRX (@Biotechnology) price change was +13.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.58%. For the same industry, the average monthly price growth was +26.31%, and the average quarterly price growth was +25.79%.

Reported Earning Dates

MDGL is expected to report earnings on Feb 22, 2024.

RXRX is expected to report earnings on Mar 20, 2024.

Industries' Descriptions

@Biotechnology (+5.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for MDGL with price predictions.
OPEN
A.I.dvisor published
a Summary for RXRX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MDGL($3.9B) has a higher market cap than RXRX($1.41B). RXRX YTD gains are higher at: -3.891 vs. MDGL (-23.521). RXRX has higher annual earnings (EBITDA): -272.42M vs. MDGL (-336.4M). RXRX has more cash in the bank: 387M vs. MDGL (232M). RXRX has less debt than MDGL: RXRX (51.5M) vs MDGL (117M). RXRX has higher revenues than MDGL: RXRX (46.9M) vs MDGL (0).
MDGLRXRXMDGL / RXRX
Capitalization3.9B1.41B276%
EBITDA-336.4M-272.42M123%
Gain YTD-23.521-3.891604%
P/E RatioN/AN/A-
Revenue046.9M-
Total Cash232M387M60%
Total Debt117M51.5M227%
FUNDAMENTALS RATINGS
MDGL: Fundamental Ratings
MDGL
OUTLOOK RATING
1..100
48
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
PROFIT vs RISK RATING
1..100
77
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MDGLRXRX
RSI
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
67%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
83%
Declines
ODDS (%)
Bearish Trend 26 days ago
81%
Bearish Trend 14 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
89%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYCCX269.43N/A
N/A
Rydex NASDAQ-100® 2x Strategy C
FCSGX12.72N/A
N/A
Franklin Small Cap Growth C
SSGFX43.84N/A
N/A
Sextant Growth
MSTSX10.25N/A
N/A
Morningstar Global Opportunistic Equity
FNEEX53.84N/A
N/A
American Funds New Economy 529-F-2

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with ABCL. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then ABCL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
+0.27%
ABCL - RXRX
54%
Loosely correlated
-3.93%
ABSI - RXRX
52%
Loosely correlated
+12.64%
MDGL - RXRX
50%
Loosely correlated
+4.16%
AXON - RXRX
49%
Loosely correlated
+2.06%
DNA - RXRX
48%
Loosely correlated
-1.75%
More